Drug Profile
Research programme: integrin receptor antagonists - Johnson & Johnson
Latest Information Update: 05 Mar 2008
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Amides; Small molecules
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Inflammatory bowel diseases
Most Recent Events
- 22 Sep 2005 Preclinical trials in Inflammatory bowel disease in USA (PO)
- 22 Sep 2005 Data presented at the 230th American Chemical Society National Meeting (230th-ACS-2005) have been added to the pharmacokinetics section and to the Inflammatory bowel disorders pharmacodynamics section ,
- 03 Apr 2005 Preclinical trials in Asthma in USA (PO)